| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB8966-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB89661-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-57827-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB89662-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-57967-25ul | |||
![Western Blot: UNC13D/Munc 13-4 Antibody [NB100-41385] - RBL-2H3 from Wt or shRNA Munc13-4 lentiviral stable expression whole cell lysate. 50 ug total protein. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Western-Blot-NB100-41385-img0008.jpg "Western Blot: UNC13D/Munc 13-4 Antibody [NB100-41385] - RBL-2H3 from Wt or shRNA Munc13-4 lentiviral stable expression whole cell lysate. 50 ug total protein. WB image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NB100-41385] - Staining of paraffin embedded Mouse Lung with antibody at 0.5 ug/mL (wt in A and KO in B).](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunohistochemistry-Paraffin-NB100-41385-img0006.jpg)
![Western Blot: UNC13D/Munc 13-4 Antibody [NB100-41385] - Staining of Human T-lymphocyte lysate with antibody at 2 ug/mL (35 ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Western-Blot-NB100-41385-img0007.jpg)
![Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NB100-41385] - Staining of paraffin embedded Human Thymus. Antibody at 2.5 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunohistochemistry-Paraffin-NB100-41385-img0005.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: UNC13D/Munc 13-4 Antibody [NB100-41385] - A549 cells stably expressing control shRNA (Ctrl) or Munc13-4 shRNA were left untreated (Untr) or were treated with TGFbeta-1 for 24 h, and SDS-PAGE Western blotting for indicated proteins was conducted. Image collected and cropped by CiteAb from the following publication (jcb.org/lookup/doi/10.1083/jcb.201710132), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Knockdown-Validated-NB100-41385-img0009.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: UNC13D/Munc 13-4 Antibody [NB100-41385] - SDS-PAGE Western blot of indicated proteins in MDA-MB-231 cells after stable expression of shRNA for Munc13-4 or Rab27a or a scrambled control (Ctrl). Image collected and cropped by CiteAb from the following publication (jcb.org/lookup/doi/10.1083/jcb.201710132), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Knockdown-Validated-NB100-41385-img0010.jpg)
![Western Blot: UNC13D/Munc 13-4 Antibody [NB100-41385] - Munc13-4 KD strongly impairs exosome release. (A) SDS-PAGE Western blot of indicated proteins in MDA-MB-231 cells after stable expression of shRNA for Munc13-4 or Rab27a or a scrambled control (Ctrl). (B) Culture medium from MDA-MB-231 cells either untreated or stimulated w/ 1.25 µM ionomycin for 30 min centrifuged at 1,000 g to remove cellular debris & 10,000 g to remove large extracellular vesicles. (C) The resulting 10,000-g supernatant filtered onto a nitrocellulose membrane & analyzed for CD63, CD9, ALIX, & GM130 content by antibody blotting. (D) Quantification of CD63, CD9, & ALIX blots in C are shown as exosome release as a percentage of total cellular material w/ mean values ± standard error (SE) for n ≥ 3. *, P < 0.05 for comparison w/ corresponding control samples. (E) Panc-1 or A549 cells left untreated or treated w/ TGF beta -1 for 24 h. Indicated proteins detected by SDS-PAGE Western blot. (F) Panc-1 cells left untreated or treated w/ TGF beta -1 for 24 h, & Munc13-4 levels determined by immunofluorescence. TGF beta -1–treated cells exhibited a mesenchymal morphology. Bars, 5 μm. (G) A549 cells stably expressing control shRNA (Ctrl) or Munc13-4 shRNA left untreated (Untr) or treated w/ TGF beta -1 for 24 h, & SDS-PAGE Western blotting for indicated proteins conducted. (H) Culture media supernatants (as in B) from A549 cells that either untreated or stimulated w/ 1.25 µM ionomycin for 30 min filtered onto nitrocellulose membrane & analyzed for CD63 & GM130. (I) Quantification of CD63+ exosome release shown as a percentage of total cellular material w/ mean values ± SE for n = 5. *, P < 0.05; **, P < 0.01 for comparison w/ corresponding control samples. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29930202), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41385_goat-polyclonal-unc13d-munc-13-4-antibody-3102024168395.jpg)
![Western Blot: UNC13D/Munc 13-4 Antibody [NB100-41385] - Munc13-4 KD strongly impairs exosome release. (A) SDS-PAGE Western blot of indicated proteins in MDA-MB-231 cells after stable expression of shRNA for Munc13-4 or Rab27a or a scrambled control (Ctrl). (B) Culture medium from MDA-MB-231 cells either untreated or stimulated w/ 1.25 µM ionomycin for 30 min centrifuged at 1,000 g to remove cellular debris & 10,000 g to remove large extracellular vesicles. (C) The resulting 10,000-g supernatant filtered onto a nitrocellulose membrane & analyzed for CD63, CD9, ALIX, & GM130 content by antibody blotting. (D) Quantification of CD63, CD9, & ALIX blots in C are shown as exosome release as a percentage of total cellular material w/ mean values ± standard error (SE) for n ≥ 3. *, P < 0.05 for comparison w/ corresponding control samples. (E) Panc-1 or A549 cells left untreated or treated w/ TGF beta -1 for 24 h. Indicated proteins detected by SDS-PAGE Western blot. (F) Panc-1 cells left untreated or treated w/ TGF beta -1 for 24 h, & Munc13-4 levels determined by immunofluorescence. TGF beta -1–treated cells exhibited a mesenchymal morphology. Bars, 5 μm. (G) A549 cells stably expressing control shRNA (Ctrl) or Munc13-4 shRNA left untreated (Untr) or treated w/ TGF beta -1 for 24 h, & SDS-PAGE Western blotting for indicated proteins conducted. (H) Culture media supernatants (as in B) from A549 cells that either untreated or stimulated w/ 1.25 µM ionomycin for 30 min filtered onto nitrocellulose membrane & analyzed for CD63 & GM130. (I) Quantification of CD63+ exosome release shown as a percentage of total cellular material w/ mean values ± SE for n = 5. *, P < 0.05; **, P < 0.01 for comparison w/ corresponding control samples. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29930202), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41385_goat-polyclonal-unc13d-munc-13-4-antibody-310202415523941.jpg)
![Western Blot: UNC13D/Munc 13-4 Antibody [NB100-41385] - Munc13-4 KD strongly impairs exosome release. (A) SDS-PAGE Western blot of indicated proteins in MDA-MB-231 cells after stable expression of shRNA for Munc13-4 or Rab27a or a scrambled control (Ctrl). (B) Culture medium from MDA-MB-231 cells either untreated or stimulated w/ 1.25 µM ionomycin for 30 min centrifuged at 1,000 g to remove cellular debris & 10,000 g to remove large extracellular vesicles. (C) The resulting 10,000-g supernatant filtered onto a nitrocellulose membrane & analyzed for CD63, CD9, ALIX, & GM130 content by antibody blotting. (D) Quantification of CD63, CD9, & ALIX blots in C are shown as exosome release as a percentage of total cellular material w/ mean values ± standard error (SE) for n ≥ 3. *, P < 0.05 for comparison w/ corresponding control samples. (E) Panc-1 or A549 cells left untreated or treated w/ TGF beta -1 for 24 h. Indicated proteins detected by SDS-PAGE Western blot. (F) Panc-1 cells left untreated or treated w/ TGF beta -1 for 24 h, & Munc13-4 levels determined by immunofluorescence. TGF beta -1–treated cells exhibited a mesenchymal morphology. Bars, 5 μm. (G) A549 cells stably expressing control shRNA (Ctrl) or Munc13-4 shRNA left untreated (Untr) or treated w/ TGF beta -1 for 24 h, & SDS-PAGE Western blotting for indicated proteins conducted. (H) Culture media supernatants (as in B) from A549 cells that either untreated or stimulated w/ 1.25 µM ionomycin for 30 min filtered onto nitrocellulose membrane & analyzed for CD63 & GM130. (I) Quantification of CD63+ exosome release shown as a percentage of total cellular material w/ mean values ± SE for n = 5. *, P < 0.05; **, P < 0.01 for comparison w/ corresponding control samples. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29930202), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41385_goat-polyclonal-unc13d-munc-13-4-antibody-31020241612622.jpg)
![Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NBP2-57827] - Staining in human spleen and kidney tissues using anti-UNC13D antibody. Corresponding UNC13D RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunohistochemistry-Paraffin-NBP2-57827-img0005.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NBP2-57827] - Staining in human spleen and kidney tissues using anti-UNC13D antibody. Corresponding UNC13D RNA-seq data are presented for the same tissues.")
![<b>Orthogonal Strategies Validation. </b>Western Blot: UNC13D/Munc 13-4 Antibody [NBP2-57827] - Western blot analysis in human cell line RT-4, human cell line U-251 MG, human plasma, human liver tissue and human tonsil tissue.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Western-Blot-NBP2-57827-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: UNC13D/Munc 13-4 Antibody [NBP2-57827] - Staining of human cell line U-2 OS shows localization to cytosol.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-57827-img0001.jpg)
![Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NBP2-57827] - Staining of human kidney shows low expression as expected.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunohistochemistry-Paraffin-NBP2-57827-img0003.jpg)
![Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NBP2-57827] - Staining of human spleen shows high expression.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunohistochemistry-Paraffin-NBP2-57827-img0004.jpg)
![Western Blot: UNC13D/Munc 13-4 Antibody [NBP1-31072] - Sample (30 ug of whole cell lysate) A: Jurkat B: K562 5% SDS PAGE; antibody diluted at 1:1000.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Western-Blot-NBP1-31072-img0008.jpg "Western Blot: UNC13D/Munc 13-4 Antibody [NBP1-31072] - Sample (30 ug of whole cell lysate) A: Jurkat B: K562 5% SDS PAGE; antibody diluted at 1:1000.")
![Immunocytochemistry/Immunofluorescence: UNC13D/Munc 13-4 Antibody [NBP1-31072] - Analysis of methanol-fixed HeLa, using antibody at 1:500 dilution.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31072-img0005.jpg)
![Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NBP1-31072] - Munc 13-4 Antibody [NBP1-31072] - Paraffin-embedded Stomach, using antibody at 1:100 dilution.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunohistochemistry-Paraffin-NBP1-31072-img0006.jpg)
![Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NB100-1434] - Staining of paraffin embedded human spleen. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunohistochemistry-Paraffin-NB100-1434-img0001.jpg "Immunohistochemistry-Paraffin: UNC13D/Munc 13-4 Antibody [NB100-1434] - Staining of paraffin embedded human spleen. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.")
![Western Blot: UNC13D/Munc 13-4 Antibody (2C7) [H00201294-M05] - Analysis of UNC13D expression in Jurkat (Cat # L017V1).](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-2C7-Western-Blot-H00201294-M05-img0003.jpg "Western Blot: UNC13D/Munc 13-4 Antibody (2C7) [H00201294-M05] - Analysis of UNC13D expression in Jurkat (Cat # L017V1).")
![ELISA: UNC13D/Munc 13-4 Antibody (2C7) [H00201294-M05] - Sandwich ELISA (Recombinant protein)](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-2C7-ELISA-H00201294-M05-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: UNC13D/Munc 13-4 Antibody [NBP2-57967] - Staining of human cell line SH-SY5Y shows localization to cytosol & vesicles.](http://images.novusbio.com/fullsize/UNC13D-Munc-13-4-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-57967-img0002.jpg "Immunocytochemistry/Immunofluorescence: UNC13D/Munc 13-4 Antibody [NBP2-57967] - Staining of human cell line SH-SY5Y shows localization to cytosol & vesicles.")
![Western Blot: Munc 13-4 Overexpression Lysate (Adult Normal) [NBL1-17611] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for Munc 13-4.](http://images.novusbio.com/fullsize/Munc-13-4-Overexpression-Lysate-Adult-Normal-Western-Blot-NBL1-17611-img0002.jpg "Western Blot: Munc 13-4 Overexpression Lysate (Adult Normal) [NBL1-17611] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for Munc 13-4.")